Table 4.
Comparison of pill burden and serum phosphorus by Kru at baseline
| Parameter | No Kru recorded (n = 64) |
Kru ≤3 mL/min/1.73 m2 (n = 122) |
Kru >3 mL/min/1.73 m2 (n = 72) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| BL | SO | p value | BL | SO | p value | BL | SO | p value | |
| PB pills/day* | 10.7 (0.3) | 4.4 (0.3) | <0.0001 | 10.6 (0.3) | 4.4 (0.3) | <0.0001 | 6.7 (0.3) | 3.7 (0.3) | <0.0001 |
| Serum phosphorus, mg/dL | 6.57 (0.16) | 6.21 (0.15) | 0.001 | 6.96 (0.14) | 6.52 (0.13) | <0.0001 | 5.97 (0.16) | 5.85 (0.15) | 0.22 |
| Patients with serum phosphorus ≤5.5 mg/dL | 10/64 (15.6) | 20/64 (31.3) | 0.008 | 18/122 (14.8) | 31/122 (25.4) | 0.012 | 29/72 (40.2) | 38/72 (52.8) | 0.049 |
Values are expressed as least-squared means (SE) for continuous variables, and n/n (%) for categorical variables.
p values compare summary estimates between treatment periods.
*
PB pill burden was calculated only for patients who received PB prescriptions through FreseniusRx.
BL, baseline; SO, sucroferric oxyhydroxide follow-up; Kru, residual urea clearance; PB, phosphate binder.